TECHVAULT   >  VIDEO LIBRARY  > Next Generation Sequencing

Building an NGS–Based Platform for Clinical Cancer Care

Precision therapy for cancer patients requires a highly accurate, clinically comprehensive assay capable of detecting the therapeutically relevant genomic alterations that drive an individual’s disease. Robust NGS-based assays based on solution hybrid capture of hundreds of cancer-related genes from adaptor-ligated sequencing libraries were developed and validated to deliver highly sensitive and specific detection of all classes of genomic alterations in routine clinical FFPE samples. Successful application of Foundation Medicine’s CLIA-certified, CAP accredited and NYSDOH approved tests to greater than 15,000 patient samples demonstrates that comprehensive genomic profiling, agnostic to tumor type, provides substantial actionable information to guide selection of targeted therapies.